Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
| dc.authorid | 0000-0002-7071-2471 | |
| dc.contributor.author | Makharadze, T. | |
| dc.contributor.author | Gogishvili, M. | |
| dc.contributor.author | Melkadze, T. | |
| dc.contributor.author | Baramidze, A. | |
| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Kılıçkap, S. | |
| dc.contributor.author | Gümüş, M. | |
| dc.date.accessioned | 2025-05-10T19:48:33Z | |
| dc.date.issued | 2023 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description | Congress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Madrid, SPAIN | |
| dc.description.abstract | [No abstract available] | |
| dc.description.sponsorship | European Soc Med Oncol | |
| dc.description.sponsorship | Regeneron Pharmaceuticals, Inc.; Sanofi | |
| dc.description.sponsorship | Regeneron Pharmaceuticals, Inc., and Sanofi. | |
| dc.identifier.doi | 10.1016/j.annonc.2023.09.2469 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2023.09.2469 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/11746 | |
| dc.identifier.volume | 34 | |
| dc.identifier.wos | WOS:001087480202114 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Annals of Oncology | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.title | Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3 | |
| dc.type | Conference Object |
Dosyalar
Orijinal paket
1 - 1 / 1










